Omnicell Q1 adjusted EPS beats helped by connected devices demand, raises FY outlook

Omnicell

28/04/2026 11:43

Overview

Healthcare technology provider's Q1 revenue rose 15% yr/yr to $310 mln

Adjusted EPS for Q1 beat analyst expectations

Company raised full-year 2026 non-GAAP EBITDA and EPS guidance

Outlook

Omnicell raises 2026 non-GAAP EBITDA guidance to $153 mln-$168 mln from prior range

Company lifts full-year 2026 non-GAAP EPS forecast to $1.80-$2.00

Omnicell sees Q2 2026 revenue of $307 mln-$313 mln and full-year revenue of $1.215 bln-$1.255 bln

Result Drivers

CONNECTED DEVICES DEMAND - Co said Q1 revenue growth was driven by strength in its connected device offerings

COST MANAGEMENT - Disciplined cost management contributed to improved profitability, per co

CUSTOMER ENGAGEMENT - Co said customer engagement is underway for Omnicell Titan XT and OmniSphere platforms

Company press release: ID:nBw5gLZKLa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$310 mln
Q1 Adjusted EPS
Beat
$0.55
$0.33 (8 Analysts)
Q1 Adjusted Net Income
$25 mln
Q1 Net Income
$11.36 mln
Q1 Adjusted EBITDA
$45 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Omnicell Inc is $58.00, about 54.1% above its April 27 closing price of $37.63

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 25 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)